Comparison of the effects of amino acid substitutions and β-N- vs. α-O-glycosylation on the T-cell stimulatory activity and conformation of an epitope on the rabies virus glycoprotein  by Otvos, Laszlo et al.
ELSEVIER Biochimica et Biophysica Acta 1267 (1995) 55-64 
I 
BB" 
Biochi~ic~a et Biophysica AEta 
Comparison of the effects of amino acid substitutions and fl-N- vs. 
ce-O-glycosylation on the T-cell stimulatory activity and conformation of 
an epitope on the rabies virus glycoprotein 
Laszlo Otvos, Jr. *, Georgia R. Krivulka, Laszlo Urge, Gyorgyi I. Szendrei, Laszlo Nagy, 
Zhi Q. Xiang, Hildegund C.J. Ertl 
The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA 
Received 17 November 1994; revised 20 January 1995; accepted 23 February 1995 
Abstract 
The first potential N-gly,zosylation site of the rabies virus glycoprotein, the antigen that carries epitopes for glycoprotein-specific 
T-cells and virus neutralizing antibodies, is glycosylated inefficiently. Recently, we showed that addition of a /3-N-acetyl-glucosamine 
moiety to the asparagine r sidue in the corresponding synthetic fragment V V E D E G C T N L S G F (amino acids 29-41), significantly 
diminished the T-cell stimulatory activity and reduced the characteristic ot-helicity of the peptide. The amino acid sequence of the 
glycoprotein this region e~:hibits some degree of variability among different rabies virus and rabies virus related strains, including the 
replacement of the asparagine residue with aspartic acid or threonine. In the current study, stimulation of a specific T-cell clone by 
various viral strains and appropriate tridecapeptide sequences and their analogs was investigated. The T-cell recognition pattern of the 
rabies and rabies-related viruses was identical to that of the synthetic peptides representing the respective pitope sequences. While the 
asparagine could be replaced without complete loss of T-cell stimulatory activity, amino acid modifications at the C-terminus of the 
peptide were not tolerated. I~L contrast to glycosylation of the asparagine, coupling of an N-acetyl-galactosamine moiety at the serine, or 
galactosyl-N-acetyl-galactosamine moieties at the threonines preceding or replacing the asparagine (all O-linked sugars in the natural 
a-anomeric onfiguration) resulted in epitopes that lowered rather than abolished the T-cell stimulatory activity. All non-glycosylated 
peptides assumed a low-to-medium helicity in trifluoroethanol. O-glycosylation was more efficient han N-glycosylation i breaking the 
helical conformation of the peptides to result in the formation of reverse-turns or unordered structure. 
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1. Introduction 
The glycoprotein of tile rabies virus (RABV) is the 
focus of many studies. The glycoprotein is the only viral 
antigen that if presented either as intact protein [1,2] or as 
synthetic subunit peptide-vaccine [3,4] is able to induce 
virus-neutralizing antibodies crucial for protection against 
Abbreviations: MHC, major histocompatibility complex; RP-HPLC, 
reverse-phase high performance liquid chromatography; CD, circular 
dichroism; TFE, 2,2,2-trifluoroethanol; TcR, T-cell receptor; ERA, Eve- 
lyn-Rokitnicki-Abelseth; FBS, fetal bovine serum; BPL, /3-propiolactone; 
DMEM, Dulbecco's modified Eagle's medium; RABV, rabies virus; 
LEP, low egg passage 
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viral spread. The glycoprotein of RABV has been used to 
study core glycosylation mechanisms of glycoproteins [5,6]. 
The amino acid sequence of this protein contains three 
potential N-glycosylation sites [7] of which only sites II 
and III may be utilized in some of the viral strains [8]. 
Although within the virus, glycosylation of Asn 37 (site I) is 
inefficient, it is still sufficient to support cell surface 
expression in cells transfected with a genetically engi- 
neered mutant protein [5]. These studies also demonstrated 
that non-glycosylated glycoprotein fails to be transported 
to the cell surface. The region around glycosylation site I 
comprises one of the major antigenic target for B-cells [9], 
and its activity is severely affected by point mutations [10]. 
This domain also carries a major T helper cell epitope [11]. 
The amino acid sequence around glycosylation site I 
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varies somewhat among viral strains [12,13]. The most 
interesting mutation, when compared with the standard 
Evelyn-Rokitnicki-Abelseth (ERA) strain [7], is the substi- 
tution of the Asn 37 itself with Thr in the Duvenhage-6 
(Duv-6; European bat virus I) strain (W. Wunner, personal 
communication), a rabies-related virus strain, and with Asp 
in the Flury low egg passage (LEP) strain [12]. These 
changes conceivably contribute to the glycosylation site, 
since Thr can also be glycosylated, and Asn ~ Asp changes 
have been noted for influenza virus laboratory mutants at 
N-glycosylation sites [14]. Moreover, Ser 39 is replaced in 
the Duv-6 strain with Thr, and the resulting TTLTP se- 
quence is an ideal candidate for Thr glycosylation [15]. 
The Asn is still present in Mokola virus (MOKV; another 
rabies-related virus) [16], but is shifted one residue closer 
to the N-terminus which results in the deletion of the 
natural N-glycosylation motif [17]. Other, non-glycosyla- 
tion-related single amino acid mutations include residues 
just preceding Asn 37 in the RABV challenge virus standard 
(CVS-11) strain [18] or following the Asn 36 in MOKV 
[12]. 
We recently described a synthetic peptide (VF13N) 
which corresponds to amino acids 29-41 of the ERA 
strain, with the sequence VVEDEGCTNLSGF, that stimu- 
lates the D2rab.gp CD4 + T-cell clone at peptide concen- 
trations as low as 0.04 /zg/ml [19]. Since T helper cell 
epitopes are not expected to be shorter than 13 amino acid 
residues [20], peptide VF13N may represent the minimal 
epitope sequence. As such, it is a good model to investi- 
gate the effect of the antigenic variability of the glyco- 
protein around glycosylation site I on the T-cell stimula- 
tory activity. Because peptide VF13N has such strong 
T-cell stimulatory properties, we used it recently to investi- 
gate the possibility of developing T-cell agonist or antago- 
nist glycopeptides [19]. The stimulation of the D2rab.gp 
T-cell clone is abolished when an N-acetyl-glucosamine 
(GlcNAc) moiety is incorporated into the asparagine 
residue of VF13N in a natural /3-anomeric configuration. 
For a different glycopeptide, we showed that the lack of 
the T-cell stimulatory activity of an internally glycosylated 
variant of the major immunodominant epitope of the RABV 
nucleoprotein s due to the glycopeptide's inability to bind 
to major histocompatibility complex (MHC) [19]. In agree- 
ment with our findings, two recent papers demonstrate hat 
internally glycosylated T-cell epitopes of extracellular ori- 
gin usually lose their ability to bind to MHC [21,22]. This 
loss of MHC binding appears to be independent of the 
amino acid host of the sugar, that is, regardless of whether 
the carbohydrate side-chain is conjugated to serine or 
asparagine [22]. All sugars were attached to the amino 
acids in /3-anomeric configuration and the serine carried a 
pentamer of D-glucose. The anomeric configuration of 
sugars in the extracellular domain of natural O-glyco- 
proteins is, however, c~, and the protein-linked carbo- 
hydrate moiety is usually N-acetyl-galactosamine 
(GalNAc). The presence of a Thr 36 residue just preceding 
Asn 37 in the ERA strain, as well as the observed Asn 37 
Thr 37 mutation, provides a model to study the effect of 
c~-linked O-glycosylation on T-cell stimulatory activity by 
allowing a direct comparison of the /3-N- vs. c~-O-glyco- 
sylation of Asn or Thr (the correct stereochemistry in 
natural glycoproteins) in the same position in the peptide 
and the resulting influence on the conformation, as well as 
on MHC binding and T-cell recognition. 
2. Materials and methods 
2.1. Animals 
Female C3H/He mice were purchased from The Jack- 
son Laboratories (Bar Harbor, ME, USA) and were used 
between the ages of 7-10 weeks. 
2.2. Experimental 
Synthetic peptides 
Peptides were synthesized on solid-phase using a Milli- 
gen 9050 automated peptide synthesizer employing stan- 
dard Fmoc-methodology [23]. Detailed methodology for 
synthesis and circular dichroism (CD) analysis of the 
N-glycosylated peptide has been published earlier [19,24]. 
Fmoc-Thr-a(Ac 4Gal -1 ~ 3/3-Ac 2GalNAc)-OH, purchased 
from Bachem (Torrance, CA, USA) was coupled in stoi- 
chiometric amounts to reduce cost. Peptides were cleaved 
off the solid support by trifluoroacetic acid. Deacetylation 
of the sugar-hydroxyl groups was accomplished by a 5-min 
treatment with 0.1 M NaOH at room temperature followed 
by immediate neutralization [25]. In our experience, the 
targeted ester hydrolysis proceeds much faster than the 
unwanted /3-elimination. After cleavage, non-glycosylated 
peptides were purified, and glycopeptides and contaminat- 
ing non-glycosylated analogs were separated by reverse- 
phase high performance liquid chromatography (RP- 
HPLC). The final products were characterized by sugar-re- 
sponsive amino acid analysis [26] and laser-desorption 
mass spectroscopy. Table 1 lists the synthetic peptides, the 
RP-HPLC retention times and the mass spectroscopy eaks. 
Cell lines 
BHK-21 cells were maintained in vitro in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 
10% fetal bovine serum (FBS) and antibiotics. The 
D2rab.gp T-cell line was derived from splenocytes of 
C3H/He mice immunized with a vaccinia-rabies glyco- 
protein recombinant virus [2]. Splenocytes were restimu- 
lated in vitro with /3-propiolactone (BPL)-inactivated 
RABV of the ERA strain (ERA-BPL). T-cells were main- 
tained thereafter by weekly subculture on irradiated (1700 
rads) C3H/He splenocytes pretreated with ERA-BPL virus 
(1 /~g/108 cells) and 10% rat concanavalin A supernatant, 
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and later subcloned as described previously [27]. The 
T-cell line and clones responded to ERA-BPL virus and 
the VF13N peptide as measured by proliferation and cy- 
tokine release (interleukin-2 and interferon-y). The 
D2rab.gp T-cell line expresses Thy-1.2 and CD4, but fails 
to express CD8 molecules, in agreement with its class I1 
restricted nature. The RABV nucleoprotein-specific T- ell 
hybridoma line, 9C5.D8-H (a fusion product of BW5147 
myeloma cells and a helper T-cell clone of C3H/He 
origin), has been described in detail [27]. HT-2 cells, a 
lymphokine-dependent T-cell line, was maintained in 
DMEM supplemented with 10% FBS, 10 5 M 2-mer- 
captoethanol, and 10% rat concanavalin A supernatant. 
Vi ruses  
Rabies virus and rabies-related viruses were grown on 
BHK cells. Viruses were purified, titrated, and inactivated 
as described [28]. The RABV strains used were: ERA, 
PV-2 (Pasteur virus), CVS-11, Flury LEP, PM (Pitman- 
Moore), and the rabies-related viruses used were: MOKV 
and Duv-6 (Poland isolate of European bat virus I species) 
[13,17]. 
Proliferation assay 
Irradiated C3H/He mouse splenocytes (5 • 105) in 100 
/xl of DMEM supplemented with 10 -5 M 2-mercapto- 
ethanol and 2% FBS in 96-well round-bottom icrotiter 
plates were co-cultured with antigen at the indicated con- 
centration i  25 /xl medium for 30 min at 37 ° C. D2rab.gp 
T-cells (2. 10 4) were  then added in 50 /zl of medium. 
Proliferation of T-cells was measured 48 h later following 
a 6-h [3H]thymidine pulse [27]. 
Cytokine release assay 
The T-cell hybridoma was tested for recognition of 
peptides presented by irradiated H-2 compatible spleno- 
cytes by a lymphokine release assay as described [27]. 
CD 
CD spectra were recorded on a Jasco J-720 instrument 
at room temperature in 0.2-0.5 mm path-length cells. 
Spectroscopy grade trifluoroethanol (TFE) was used as 
solvent. Peptide concentration was about 0.5 mg/ml (ex- 
cept the dilution study), determined each time by quantita- 
tive HPLC. The CD spectra of Figs. 3 and 4 are baseline- 
corrected and smoothed by the algorithm provided by 
Jasco. The CD contribution of the GlcNAc in the Asn-lin- 
ked glycopeptide was estimated by subtracting the CD 
spectrum of 1,2-diacetamido-l,2-dideoxy-/3-D-gluco- 
pyranose [24]. In keeping with our earlier reports [1,29], 
the spectral contribution of the O-glycosides was not 
subtracted. Mean residue ellipticity [0]mR is expressed in 
deg cm2/dmol using mean residue weights calculated 
from the molecular weight of the peptides or glycopeptides 
divided by the number of amino acids present in the 
sequences. 
3. Results 
3.1. T-cell stimulation: viruses 
The RABV glycoprotein shows a substantial degree of 
amino acid sequence variability between rabies and 
rabies-related viruses. Nevertheless, the amino acid se- 
quence near the N-terminus recognized by the D2rab.gp 
Table 1 
Synthetic peptides and their characterization 
Peptide Sequence a Virus species (strain) Mass RP-HPLC 
spectroscopy retention time 
(M + H) b (min) c 
Peptides corresponding to different viral strains: 
VF 13N VVEDEGCTNLSGF Rabies (ERA) 1370 26.7 
IFI 3Duv-6 IVEDEGCTTLTPF Duvenhage-6 (Eur-bat virus I) 1427 30.2 
LF13Mok LSEEEGCNAESSF Mokola 1401 37.0 
VF12Lep VEDEGCTDLSGF Rabies (Flury LEP) 1271 27.1 
Analog peptides: Modifications: 
VFI3N(G) e VVEDEGCTN-/3 (GIcNAc)LSGF Asn-/3-sugar 1573 26.0 
VF13N(T-G) VVEDEGCT-a (GaI-GalNAc) d NLSGF Thr-a-sugar 1755 (M + Na) 25.1 
Ac-VF 13N Ac-VVEDEGCTNLSGF Acetylation 1430 (M + Na) 32.2 
Ac-VF13N(S-G) Ac-VVEDEGCTNLS-a (GalNAc) GF Ser-a-sugar 1636 (M + Na) 30.2 
VFl 3T VVEDEGCTTLSGF (ERA) N ~ T 1359 27.5 
VFI3T(G) VVEDEGCTT-o~ (GaI-GalNAc) dLSGF (ERA) N --, T-a-sugar 1743 (M + Na) 25.4 
a All synthetic peptides were C-terminal amides and with the exception of Ac-VF13N and Ac-VF13N(S-G) had free amino termini. 
b The accuracy of the laser-desorption mass spectrometer we used in the indicated mass range is _+ 3 Da. 
c The peptides were injected to the C18 column (i.d.: 4.6 x 250 mm) in 0.1% aqueous trifluoroacetic acid containing 5% acetonitrile, and were eluted from 
the column with a 1.33%/min linear gradient of acetonitrile in 0.1% trifluoroacetic acid. 
d The anomeric onfiguration of 1.he sugar is Gal(/31 ~ 3)GalNAc( a 1 -~ O). 
e This peptide is referred to as VF13G in [19] and [24]. For consistency with the other peptide names in this paper, here we refer to it as VF13N(G). 
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T-cell clone, which surrounds one of the three potential 
N-glycosylation sites of the protein is fairly well con- 
served. To test for conservation at a functional evel, the 
D2rab.gp T-cell clone was tested for proliferation in re- 
sponse to antigen derived from a number of different viral 
strains. As a control for the viral preparation, a RABV 
nucleoprotein specific T-cell hybridoma was included for 
those virus strains that failed to induce proliferation of the 
D2rab.gp T-cell clone. As shown in Table 2, the D2rab.gp 
T-cell clone proliferated after stimulation by ERA virus, 
CVS-11, PV-2, and Flury LEP, but failed to respond to the 
PM strain of RABV. The T-cell line also failed to recog- 
nize the two rabies-related viruses, MOKV and Duv-6. 
Two of the viral strains that gave negative results with the 
D2rab.gp cell line, i.e., PM and Duv-6, were able to 
stimulate the control T-cell line, i.e., the 9C5.D8 hy- 
bridoma that is directed to the conserved nucleoprotein. 
We did not test the 9C5.D8 hybridoma with MOKV virus 
because this T-cell line does not recognize the nucleopro- 
tein of MOKV [27]. 
3.2. T-cell stimulation: non-glycosylated peptides 
The pattern of T-cell recognition of a nested set of 
non-glycosylated synthetic peptides trictly follows that of 
the viruses, indicating that the D2rab.gp T-cell clone is 
specific for the ERA-derived VF13N sequence. Any differ- 
ences in the ability of the various strains to stimulate the 
T-cell clone appear to be due to minor changes in the 
amino acid sequence around N-glycosylation site I of the 
RABV glycoprotein. Replacement of the Asn with Asp 
(peptide VF12Lep) or Thr (peptide VF13T) resulted in a 
decreased (10-fold) T-cell stimulation, but the T-cell activ- 
ity was still significant (Fig. 1). The reduced T-cell stimu- 
latory activity of peptide VF12Lep might have been due to 
the shortened length ( -  1 amino acid) of the peptide. In 
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Fig. 1. Response of T-cells to peptide VF13N and peptides corresponding 
to different viral strains. Full squares (a) peptide VFI3N (ERA strain); 
full circles (b) VF12Lep (Flury LEP strain); empty triangles (c) VF13T 
(ERA analog); empty circles (d) IF13Duv-6 (Duvenhage-6 strain of 
European bat virus I); and empty squares (e) LFI3Mok (Mokola virus). 
Medium control: 53 + 11 cpm. 
exclude the variable Val in position 1, and to verify an 
earlier observation that locates the immunodominant se- 
quence C-terminal to Asp 32 [11]. Indeed, amino acid muta- 
tions between the Asn and the C-terminal Phe eliminated 
the T-cell stimulatory activity. Peptides IF13Duv-6 and 
LF13Mok failed to induce any T-cell response at concen- 
trations as high as 5-20 tzg (Fig. 1). In addition to the 
Asn ~ Thr substitution, in peptide IF13Duv-6, Set  39 is 
replaced with Thr, and Gly 4° is replaced with Pro. Seven 
out of 13 amino acids are modified in peptide LF13Mok. 
The positive T-cell response to peptides VF12Lep, VFI 3T, 
and Ac-VF13N (Table 3), as well as the unchanged amino 
acids between Val 3° and Thr 36 in peptide IFl3Duv-6 
Table 2 
T-cell response to RABV species and strains 
T-cell clone [3H]Thymidine incorporation (cpm + S.D.) 
D2rab.gp 9C5.D8 
Virus dose BPL-inactivated 5 txg/ml 1 /xg/ml 25/xg/ml  5 /xg /ml  
ERA 14,876 5:454 
PM 1,641 + 311 
PV-2 17,327 4- 237 
MOK 767 5:301 
DUV-6 (Eur bat I) 390 5:90 
CVS-11 12,851 5:2,572 
None (medium control) 
UV-inactivated 1:10 
ERA 24,679 + 5,405 
LEP 26,005 5:6,922 
None (medium control) 
1,085 ± 242 
51 + 16 
24,745 + 1,965 8,492 + 607 2,035 + 206 
827 _ 263 6,732 + 288 4,523 + 226 
19,761 -t- 1,276 Not tested 
700 + 158 Not tested 
538 + 13 10,231 + 1,227 8,334 + 669 
21,366 + 2,412 Not tested 
410 5:10 
1:100 
18,459 5:2,822 Not tested 
25,183 + 443 Not tested 
The table represents results from two different sets of experiments. In the first set, the T-cell clone or the hybridoma were tested using BPL inactivated 
purified virus adjusted to 5 /~g and l /xg of protein/ml. In the second set of experiments, ultraviolet light-inactivated virus was used at a l:10 and l:100 
dilution. The assay was conducted as described in Section 2. 
L. Otvos, Jr. et al. / Biochimica et Biophysica Acta 1267 (1995) 55-64 59 
Table 3 
T-cell response and conformation of N-terminally acetylated VF13N 
peptide and its Ser-glycosylated analog 
Peptide [ 3 H]Thymidine incorporation (cpm + S.D.) 
1 /zg 0.2 /xg 0.04/xg a-Helix 
content 
Ac-VF13N 9,614+948 2,136+393 103+89 22% 
Ac-VF 13N(S-G) 7,321 ___ 694 3,022 + 173 213 + 208 0% 
The T-cell stimulation assay was conducted as indicated in Table 2. The 
calculation of the o~-helix content was based on the ellipticity at 208 nm 
[33]. The medium control resuhed in a [3H]thymidine incorporation of 
45 + 18 cpm. 
compared to VF13N indicate that the amino acid alter- 
ations responsible for the lack of the T-cell stimulatory 
activity of peptides IF13Duv-6 and LFI3Mok are located 
at the C-terminal end of the sequence. 
3.3. T-cell stimulation: glycopeptides 
We have previously reported that incorporation of an 
t-linked monosaccharide moiety into Asn 37 [glycopeptide 
VF13N(G)] diminishes the T-cell stimulatory activity of 
peptide VF13N [19]. To compare the effect of the stereo- 
chemically correct /3-N- vs. a-O-glycosylation  class II 
MHC-restricted T-cell recognition, the possible O-linked 
sugar hosts, Thr 36 and Ser 39, were glycosylated with di- or 
monosaccharides [glycopeptides VF13N(T-G) and Ac- 
VF13N(S-G), respectively]. To comply with the rules of 
extracellular domains of natural glycoproteins, the 
peptide-linked sugar was GlcNAc for N-glycosylation, and 
Q, 
0 °~ 
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Fig. 2. Response of T-cells to VF13 analog peptides and glycopeptides. 
Full squares (a) non-modified peptide VF13N; empty circles (b) peptide 
VF13T. The glycopeptides are as follows: empty triangles (c) O-glyco- 
sylated peptide VF13T(G); empty squares (d) O-glycosylated peptide 
VF13N(T-G); and full circles (e) N-glycosylated peptide VF13N(G). 
Medium control: 57 4- 16 cpm. While ot-O-glycosylation retained some of 
the T-cell stimulatory activity, fl-N-glycosylation fully abolished it. 
GalNAc for O-glycosylation. Addition of an a-linked 
carbohydrate side-chain to the Ser 39 (residue 11 in the 
peptide) did not affect the T-cell stimulatory activity, and 
peptide Ac-VF13N(S-G) still stimulated the D2rab.gp T- 
cell clone at very low (0.2 /xg/ml) peptide concentrations 
(Table 3). The T-cell stimulatory activity was maintained, 
but at a considerably reduced level for the Thr-glyco- 
sylated VF13N peptide [VF13N(T-G), Fig. 2]. By increas- 
ing the peptide concentration (10-20/zg/ml),  strong T-cell 
stimulation was observed for this glycopeptide, in contrast 
with the N-glycosylated analog. /3-N-glycosylated peptide 
VF13N(G) did not stimulate the T-cell clone even at these 
high peptide concentrations (Fig. 2). Finally, we incorpo- 
rated a disaccharide into the second Thr residue of peptide 
VF13T [glycopeptide VF13T(G)]. This glycopeptide car- 
ties an a-linked sugar at the same amino acid position 
(that is, residue 9 in the peptide, and 37 in the full protein) 
as glycopeptide VF13N(G) carries its fl-linked sugar. As 
Fig. 2 demonstrates, glycosylation just slightly reduced the 
T-cell stimulatory activity of peptide VF13T, and a posi- 
tive T-cell response was detected for the a-linked gly- 
copeptide at a peptide concentration as low as 2 /zg/ml. 
This finding demonstrates clearly a major difference in the 
T-cell recognition of a-O- vs. fl-N-glycosylation of the 
same class II MHC-restricted epitope. 
3.4. Binding of peptides to MHC 
The lack of responsiveness of T-cells to a peptide may 
be due to inadequate binding of peptide to the MHC 
determinants or to lack of recognition by the T-cell recep- 
tor (TcR) of the peptide-MHC complex. To differentiate 
between these two possibilities, inhibition studies were 
performed with peptide IF13Duv-6 and glycopeptide 
VF13N(G) that did not stimulate the VF13N-specific T- 
cells. Peptide IF13Duv-6 at 20 ~g/ml  concentration 
caused no stimulation of the D2rab.gp cell clone, and it 
could only partially (45%) inhibit the response to peptide 
VF13N (Table 4). The glycopeptide marginally (18%) 
inhibited the T-cell response to the non-glycosylated par- 
ent analog (Table 4). These results indicate that minor 
changes in the amino acid sequence in peptide IF13Duv-6 
strongly affected the MHC-binding ability, and that /3-N- 
glycosylation almost abolished it. 
3.5. Conformation of peptides 
Peptide VF13N assumes a loosened and/or inducible 
c~-helix as its dominant conformation, as we demonstrated 
by CD studies performed in aqueous TFE solutions [24]. 
The a-helix content reaches 21% in neat TFE (minor 
alterations in this value may occur due to minor variations 
in the purity of different peptide batches and the determi- 
nation of peptide concentration). In this study, we com- 
pared the secondary structure of T-cell stimulatory and 
non-stimulatory peptides as well as that of MHC-binding 
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Table 4 
Competition between non-stimulatory peptides and native peptide 
VF13N a for T-cell response 
Inhibitory peptide Concentration f peptide VF 13N (/xg/ml) 
[S.I. b/% inhibition c] 
1 0 
None 6,528 + 83 [204] 32 _ 12 
20/xg/ml VF13N(G) 5,399_+477 [168/18] 45 _+27 
20/xg/ml IF13Duv-6 3,673 +_594 [101/45] 60+44 
a Twenty /xg/ml of the inhibitory peptides was incubated with irradiated 
splenocytes for 60 rain. Peptide VF13N and T-cells were subsequently 
added. [3H]Thymidine incorporation was measured in cpm as described 
in Section 2. The standard eviation of triplicate samples is given. 
b S.I., the stimulation index (first number in brackets) was calculated by 
dividing cpm of samples receiving antigen (either VF13N or 'inhibitory 
peptide') by cpm of control sample incubated in medium only. 
c Percent inhibition (second number in brackets) was calculated by using 
the formula 100-[(cpm of cells incubated in the presence of peptide 
VF13N+inhibitory peptide-cpm of cells incubated in the presence of 
inhibitory peptide only)/(cpm of cells incubated in the presence of 
peptide VF13N - cpm of control sample)] ×100. 
and MHC non-binding lycopeptides. Since peptide VF 13N 
is mostly unordered in water or when the dielectric con- 
stant of the solution is high [24], we selected undiluted 
TFE as CD solvent. TFE has been shown to mimic the 
dynamic hydrophobic-hydrophilic environment of the cell 
membrane [30] where T-cell presentation occurs [31]. Fig. 
3 shows the CD spectra of the peptides corresponding to 
different viral strains. All peptides exhibit transitional 
spectra between those of helical and type C. Type C 
spectra [32] are similar to those of a-helices [33], except 
their band intensities are significantly lower than those of 
a-helices, and the bands are somewhat blueshifted. Type-C 
spectra were measured for peptides with established type I 
( l id /3-turns [34,35] or /3-turn mixtures with significant 
type I content [36]. Due to the ambiguity of the CD of the 
different types of /3-turns as well as the conflict of the 
current curve-analyzing algorithms (Yang, Varselec, Sel- 
com, Lincomb) evaluating turn structures, quantitative 
analysis of the CD traces are not performed. Peptide 
VFI3N has the highest negative ellipticity value at 208 
nm, a measure of a-helicity [33]. The blueshift of the band 
maximum to 205 nm, and the low intensity of the 190-nm 
positive band, however, indicate that the a-helix is sub- 
stantially loosened and/or is assembled from very short 
segments [37]. This is in agreement with secondary struc- 
tural predictions [38] that propose short segments of a- 
helices and/or an extended turn system for peptide VF13N. 
The same secondary structural prediction reveals the high- 
est propensity to form a-helices for peptide LF13Mok, 
and the shape of the CD curve of this peptide was indeed 
the closest o that of classical a-helices. Classical a-helices 
in halogenated alcohols feature negative bands of almost 
equal intensity at 208 (~-Tr * transition) and 222 nm (n¢r* 
transition), and a chain-length-dependent strong positive 
~-Tr * band at 190 nm [37,39]. Since the calculated a-helix 
content [33] was approximately 10%, the presence of a 
helix with altered geometry (e.g., a 310-helix) was likely. 
The helicity was further decreased in the order IF13Duv-6 
VFI2Lep (Fig. 3). A continuous blueshift of the nega- 
tive ~-~" * band could be observed accompanied by the 
decrease in the intensities of all bands, as well as an 
increase in the intensity ratio of the 208-nm and 222-nm 
bands. All these features indicate a helix ~ turn transition. 
Peptide VF12Lep exhibited an almost ideal type C CD 
16,000 /"',\ 
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Fig. 3. CD spectra of peptide VF13N and peptides corresponding to different viral strains. Solid trace, VF13N (ERA strain); dashes, LFI3Mok (Mokola 
virus); dots and dashes, IF13Duv-6 (Duvenhage-6 strain of European bat virus I); and dots, VF12Lep (Flury LEP strain of RABV). The CD spectra 
indicate a continuous helix ~ turn transition in the above listed order of the peptides. 
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Fig. 4. CD spectra of VF13 analog peptides and glycopeptides. Solid trace, (a) non-modified peptide VF13N; dots, peptide VFI 3T. The glycopeptides are 
as follows: solid trace, (b) N-glycosylated peptide VF13N(G); dashes, O-glycosylated peptide VFI3N(T-G); and dots and dashes, O-glycosylated peptide 
VF13T(G). Generally, O-glycosylation was more ffective inbreaking the ordered structure than N-glycosylation. 
spectrum, characteristic of type I r-turns [34]. This peptide 
is the shortest used in this study, and this is reflected by its 
having the lowest level of helicity. The conformation of 
the peptides appear to be independent of the concentration 
(in the 0.1-0.5 mg/ml  range). 
Glycosylation of the Asn residue in peptide VF13N 
breaks the helical characte, r and the proposed reverse-turns 
are stabilized [19,24], a filading which is further supported 
by this study [compare solid traces (a) and (b) in Fig. 4]. 
The spectral characteristics of the /3-N-glycosylated pep- 
tide were similar to those of the non-modified analog, but 
the band intensities were considerably decreased. Glyco- 
sylation of Thr 8 (Thr 36 in the protein) that precedes the 
Asn residue resulted in a peptide conformation i which no 
helical character could be found (dashed trace in Fig. 4). 
The nqr * band of the CD of peptide VF13N(T-G) almost 
disappeared, the negative 7r~-* band was blueshifted to 
203 nm and the intensity of the positive 7r~- * band further 
decreased. Replacement of the Asn with Thr in non-glyco- 
sylated peptide VF13N (peptide VF13T) resulted in a 
somewhat decreased a-helicity (dots in Fig. 4), supporting 
the predictive rules [40]. Peptide VF13T was still more 
helical than any of the glycosylated versions. Glycosyla- 
tion of the Thr residue of this peptide [glycopeptide 
VFI3T(G)] produced the least ordered of all the VF13 
peptides studied. Glycopeptide VF13T(G) exhibited a 
dominant negative CD band at 201 nm and shoulders 
around 220 nm as well as a weak positive band at 187 nm. 
These spectral features were not fully characteristic, but 
resembled those of polypeptides in unordered conforma- 
tion [37]. The decrease in ordered structure after the Asn 
Thr mutation of the non-glycosylated peptide pair was 
also observable in the appropriate O-glycopeptide pair 
having the same amino acid mutation. 
4. Discussion 
Minor changes in the primary amino acid sequence or 
in the anomeric configuration of incorporated sugars in 
proximity to the predicted N-glycosylation site I pro- 
foundly affected the T-cell stimulatory activity of the 
glycoprotein of RABV and its fragments. This finding is in 
contrast with earlier indications that regions of the glyco- 
protein involved in the T-cell response were less variable 
than those eliciting the B-cell response and were suggested 
to be the best targets to increase the effect of vaccines 
[12,41]. The lack of T-cell responses to some of the 
mutated non-glycosylated and the /3-N-glycosylated pep- 
tides was apparently largely due to the inability of the 
modified peptides to bind to MHC. The amino acid alter- 
ations between peptides VF13N (stimulatory for the 
D2rab.gp T-cell clone) and IF13Duv-6 (non-stimulatory) 
are few in number, and conservative in nature. Ile of 
IF13Duv-6 is substituted for Val of VFI3N in position 1, 
Thr is substituted for Ser in position 11, and Pro is 
substituted for Gly in position 12. These modifications 
occur at the termini of the peptides, which occupy the open 
ends of MHC class II antigens [42]. Since class II MHC 
molecules bind peptides with altered termini [19,43] 
promiscuously, it is intriguing that peptide IF13Duv-6 did 
not maintain its ability to bind the MHC determinant. A 
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similar single inter-strain amino acid mutation is found in 
the major class II-restricted immunodominant epitope, 31D, 
corresponding to the RABV nucleoprotein [27]. The Met in 
this peptide from the ERA strain is replaced with an Ile in 
the peptide from the PV strain. The ERA 31D-specific 
hybridoma 9C5.D8 fails to recognize the PV-peptide, al- 
though the PV-peptide binds to the MHC [27]. 
We incorporated a-O-linked sugars to three different 
positions of the VFI3 peptide to obtain insights into 
putative immunological nd conformational differences be- 
tween the stereochemically correct /3-N- vs. a-O-glyco- 
sylation. The RABV glycoprotein is glycosylated at the 
second and third potential N-glycosylation sites [8], but 
O-glycosylation has not been reported yet. Concomitant 
glycosylation of adjacent Thr-Asn sequences occurs in 
other proteins, as for example both Thr 25 and Asn 26 [44] 
are glycosylated in human glycophorin A [15]. All three 
a-O-glycosylated VF13 peptide analogs retained their abil- 
ity to stimulate the D2rab.gp T-cell clone. Either no reduc- 
tion in the stimulatory activity was found, i.e., when Set, 
the third amino acid from the C-terminus, was glyco- 
sylated, or glycosylation brought about some decrease in 
the stimulatory activity, i.e., when Thr five amino acids 
from the C-terminus was glycosylated. Glycosylation of 
the Thr six amino acids away from the C-terminus reduced 
the T-cell activity even further. This reduction possibly 
reflects the increasing ability of the sugars to exert nega- 
tive effects on the peptide-class II MHC interaction through 
blocking the centrally located anchor positions [43]. It is 
interesting to note that while conservative amino acid 
mutations of the C-terminal Ser and Gly residues of the 
ERA peptide (VF13N) resulted in a loss of MHC- (and 
perhaps TcR-) binding for peptide IF13Duv-6, glycosyla- 
tion of the same Ser did not affect he T-cell activity at all. 
All of our peptides were purified to homogeneity and the 
HPLC retention times clearly indicate that the glycopep- 
tide preparations were not contaminated with non-glyco- 
sylated peptide. We tested peptides VFI3N, VFI3N(G), 
VF13T, and VF13T(G) for alteration in the medium that 
contained splenocytes and/or 2% FBS. No peptide degra- 
dation or deglycosylation was found by RP-HPLC in the 
2-16 h examination period. Taken together, these findings 
concerning the T-cell stimulation indicate that, in terms of 
T-cell activity, O-glycosylation of the epitopes was better 
tolerated than amino acid mutations. 
Covalent couping of a /3-1inked GlcNAc moiety onto 
the Asn residue fully abolished the T-cell stimulatory 
activity due to the glycopeptide's inability to bind to class 
II MHC. The general tendency of /3-1inked internal glyco- 
sylation to prevent epitope binding to class II MHC was 
demonstrated recently for both N- and O-linked glycopep- 
tides [22]. Glycopeptides have also been shown to inhibit 
allospecific cytotoxic T-lymphocyte recognition in an 
MHC-specific manner [45]. The results we report indicate 
a major difference in the effect of the anomeric onfigura- 
tion of the peptide-linked sugar moiety on the MHC 
recognition and could be reproduced by using the 31D 
peptide family (the MHC-restricting element for this rabies 
epitope is I-Ek). While /3-N-glycosylation f the sequence 
A V YTR I  MMN G G RL  KR fully abolished the 
peptide's ability to bind MHC and to stimulate the corre- 
sponding 9C5.D8 T-cell hybridoma [19], incorporation of 
a-linked sugar to the threonine only slightly reduced the 
T-cell stimulating activity (data not shown). If our exam- 
ples can be generalized, it would mean that natural O- 
glycosylation (with GalNAc or higher sugars starting with 
GalNAc) of class II-restricted T-cell epitopes can be toler- 
ated, but N-glycosylation (with GIcNAc) cannot. This 
would also explain why only very few (if any) N-glyco- 
sylated MHC-binding peptides have been isolated so far 
[46]. We did not find any removal of either N- or O-linked 
sugars in 2% FBS for a 2-h period that would be sufficient 
for MHC binding of the deglycosylated analogs. Similarly, 
no sugar loss was detected by HPLC when the glycopep- 
tides were incubated with C3H/He splenocytes for 16 h. 
Although the examined supernatant likely reflects the anti- 
gen composition ear the cell membrane, differences in the 
intracellular removal of the carbohydrate during the T-cell 
assay may still occur. Studies of this possibility lie outside 
the scope of this report. 
In contrast o the helper T-cells, cytotoxic T-lympho- 
cytes are stimulated by peptide fragments of intracellular 
synthesized and/or processed protein [47]. /3-O-linked 
GIcNAc moiety was detected almost exclusively on nu- 
clear and cytosolic proteins [48]. Most recently it was 
demonstrated that a class I MHC-binding peptide can be 
modified by both a- and /3-1inked O-glycosylation as well 
as by fi-linked N-glycosylation without affecting its bind- 
ing to MHC class I, provided the modifications do not 
involve amino acids located at anchor positions [49]. 
The ability of some MHC proteins to discriminate 
between a- and /3-1inked carbohydrates on epitopes they 
bind sheds new light on two earlier theories [50-52]. 
Based on indirect evidence, Roth proposed that the glyco- 
syltransferases may be evolutionary precursors of MHC 
proteins, and that some MHC proteins at least may have 
retained glycosyltransferase activity [50,51]. Blanden and 
co-workers [52] speculated that the antigenic patterns re- 
sponsible for T-cell triggering may be established by 
glycosylation of foreign polypeptides using the batteries of 
glycosyltransferases normally concerned with production 
of histocompatibility antigens in stimulator cells, and that 
the TcR may also be wholly or partly composed of glyco- 
syltransferases [52]. Considering the stereospecificity of
the glycosyltransferases [53] that might have been inher- 
ited by the MHC molecules, the glycosyltransferase nces- 
try of MHC could be further supported by our findings. 
Nevertheless, the relationship between some MHC 
molecules and some glycosyltransferases is till a subject 
of debate. Some weak sequence similarities exist between 
some MHC proteins and some of the relatively small 
number of mammalian glycosyltransferases for which se- 
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quences are known. On the other hand, sequence similari- 
ties among the different families and classes of mam- 
malian transferases themselves are also weak and non-ex- 
istent. Critical sequence comparisons between MHC pro- 
teins and glycosyltransfelrases will be possible when the 
number of published tran~fferase quences approaches the 
number of MHC sequences. 
Harding and co-workers proposed that T-cells directed 
to N-terminally glycosylated peptides recognize a peptide 
conformation specific to glycopeptide-MHC complexes, 
and this recognition does not involve specific interaction 
between the carbohydrate moiety and the TcR [54]. Peptide 
VFI 3N conformation exhibits features of inducible and/or 
loosened a-helices, but this study failed to link the helicity 
of the epitopes to T-cell stimulatory activity. Although the 
two inactive peptides IFl3Duv-6 and LF13Mok are less 
helical than VF13N, the helicity of the immunologically 
active peptide VF13T was similarly reduced, and peptide 
VF12Lep also stimulated the T-cell clone, although not 
helical at all. The limited importance of the a-helicity in 
binding glycopeptides to MHC has been noted earlier [22]. 
The same findings hold 1:rue for the conformation-MHC 
binding properties of the glycopeptides. Although O- 
glycosylation was more efficient han N-glycosylation i
breaking the helical structare of peptide VF13N, O-glyco- 
sylated peptides retained their ability to bind MHC, but the 
N-glycosylated peptide did not. It appears that a-O-glyco- 
sylation brought about the breakage of the helix without 
any significant stabilization of the turn. This is in full 
agreement with our earlier findings that demonstrated a 
less ordered structure following O-glycosylation than fol- 
lowing N-glycosylation of an octapeptide corresponding to
the glycoprotein of the human immunodeficiency virus 
[29]. 
Peptides the size of VF]I3 and 31D are unlikely to adopt 
well-defined conformations in aqueous olutions, and the 
MHC II-binding site prestLmably selects the most suitable 
conformation from the available assembly of different 
antigen secondary structures. The human equivalent of the 
mouse I-E k molecule is HLA-DR1 [55]. Since the struc- 
tures of the DRl-peptide complexes are solved [56], 
molecular modeling may be able to supplement direct high 
resolution conformational nalysis of DRl-peptide com- 
plexes to identify the binding VF13 and 31D conforma- 
tions and to visualize and explain the differences between 
a- and /3-sugar linked glycopeptide binding. 
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